- Home
- EDRY vs ATNM Comparison
EDRY vs ATNM Comparison
Compare EDRY & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | ATNM |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 45.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EDRY | ATNM |
|---|---|---|
| Price | $16.25 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 4.0K | ★ 121.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.60 | $1.03 |
| 52 Week High | $16.14 | $2.41 |
Technical Indicators
Market Signals| Indicator | EDRY | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 68.71 | 26.10 |
| Support Level | $13.64 | $1.15 |
| Resistance Level | $14.85 | $1.19 |
| Average True Range (ATR) | 0.68 | 0.06 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 83.26 | 8.70 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.